Safety and Efficacy of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery

Sponsor

PolyPid Ltd. (Industry)

Overall Status

Completed

CT.gov ID

NCT02731573

Collaborator

(none)

Enrollment

Locations

Arms

Actual Duration (Months)

Patients Per Site

0.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study is aimed to assess the anti-infective efficacy of D-PLEX over a period of 3 months post operation as well as the safety over a period of 6 months, by preventing sternal infection post cardiac surgery in patients above the age of 18, including high risk patients for infection. This study is a 2 parts study: part 1 is a single arm, part 2 is randomized controlled study.

Condition or Disease	Intervention/Treatment	Phase
Postoperative Wound Infection Superficial Incisional Postoperative Wound Infection Deep Incisional Surgical Site	Drug: D-PLEX Procedure: Open heart surgery	Phase 1/Phase 2

Detailed Description

D-PLEX is a new formulation of extended controlled release Doxycycline.

Subjects who meet the eligibility criteria and provide signed informed consent, will be enrolled into the study and will be treated with D-PLEX concomitantly with standard of care.

D-PLEX will be administered as a single application during a cardiac surgery (index procedure) immediately prior to sternal closure, as an adjunct to the standard care.

The study will assess the efficacy and safety of the controlled release antibiotic (doxycycline) by the reduction in the number of sternal infections observed during the treatment period in any subject above the age of 18 years, including patients with high risk for infection.

Additional follow up for prolonged safety assessments only, will be done as follows until 24 weeks.

Study Design

Study Type:

Interventional

Actual Enrollment :

80 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Phase Ib/II, Prospective, Multicenter, Two part study; Part 1 Open Label, Single arm & Part 2 Randomized, Single-blinded, D-PLEX Concomitantly with Standard Of Care vs. Standard of Care alone. Study population include subjects above the age of 18 years, that undergoing cardiac surgery through mid-sternotomy, including patients with high risk of infection, such as diabetes (Insulin and/or non-insulin dependent), patients with Peripheral Vascular Disease (PVD), Chronic Obstructive Pulmonary Disease (COPD), heavy smokers, Bilateral Mammary artery harvesting, and subjects administered chronic steroid treatment. Subjects who meet the eligibility criteria and provide signed informed consent, will be enrolled into the study and will be treated with D-PLEX concomitantly with standard of care (part 1) or randomized 2:1 to D-PLEX concomitantly with standard of care vs. standard of care only (part 2).Phase Ib/II, Prospective, Multicenter, Two part study; Part 1 Open Label, Single arm & Part 2 Randomized, Single-blinded, D-PLEX Concomitantly with Standard Of Care vs. Standard of Care alone. Study population include subjects above the age of 18 years, that undergoing cardiac surgery through mid-sternotomy, including patients with high risk of infection, such as diabetes (Insulin and/or non-insulin dependent), patients with Peripheral Vascular Disease (PVD), Chronic Obstructive Pulmonary Disease (COPD), heavy smokers, Bilateral Mammary artery harvesting, and subjects administered chronic steroid treatment. Subjects who meet the eligibility criteria and provide signed informed consent, will be enrolled into the study and will be treated with D-PLEX concomitantly with standard of care (part 1) or randomized 2:1 to D-PLEX concomitantly with standard of care vs. standard of care only (part 2).

Masking:

Single (Participant)

Primary Purpose:

Prevention

Official Title:

A Phase Ib/II Prospective, Multicenter, Two Part Study; Part 1 - Open Label, Single Arm & Part 2 Randomized, Single-blinded (Study to Assess Safety and Efficacy of D-PLEX Concomitantly With Standard of Care vs. Standard of Care Alone in the Prevention of Primary Sternal Infection Post Cardiac Surgery.

Actual Study Start Date :

Oct 1, 2016

Actual Primary Completion Date :

Feb 1, 2018

Actual Study Completion Date :

May 1, 2018

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment arm Subjects who meet the eligibility criteria and provide signed informed consent, will undergo open heart surgery according to standard of care with treatment by D-PLEX.	Drug: D-PLEX D-PLEX will be administered as a single application during the open heart surgery (index procedure) immediately prior to sternal closure, as an adjunct to the standard care. Procedure: Open heart surgery Subject will undergo open heart surgery according to standard of care Other Names: SOC
Other: Control arm Subjects who meet the eligibility criteria and provide signed informed consent, will undergo open heart surgery according to standard of care.	Procedure: Open heart surgery Subject will undergo open heart surgery according to standard of care Other Names: SOC

Arm

Intervention/Treatment

Experimental: Treatment arm

Subjects who meet the eligibility criteria and provide signed informed consent, will undergo open heart surgery according to standard of care with treatment by D-PLEX.

Drug: D-PLEX

D-PLEX will be administered as a single application during the open heart surgery (index procedure) immediately prior to sternal closure, as an adjunct to the standard care.

Procedure: Open heart surgery

Subject will undergo open heart surgery according to standard of care

Other Names:

SOC

Other: Control arm

Subjects who meet the eligibility criteria and provide signed informed consent, will undergo open heart surgery according to standard of care.

Procedure: Open heart surgery

Subject will undergo open heart surgery according to standard of care

Other Names:

SOC

Outcome Measures

Primary Outcome Measures

Sternal Infection identified within 90 days post-cardiac surgery. Primary sternal infection as measured by the proportion of subjects with at least 1 identified primary sternal infection within 90 days post-cardiac surgery. [Within 90 days post-cardiac surgery.]
Decrease of infection rate as measured by the proportion of subjects with at least 1 identified sternal infection within 90 days post-cardiac surgery.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Male or non-pregnant female above 18 years old
Female of childbearing potential should have a negative serum pregnancy test prior to index procedure.

Note: All female of childbearing potential must agree to use a highly effective method of contraception (such as double barrier, oral or parenteral hormonal, intrauterine device and spermicide) consistently and correctly for the duration of the study.

Subjects undergoing elective or urgent cardiac surgery, who are preoperative stable hemodynamically.
Subjects with (20≤BMI≤40)
Subjects who sign a written informed consent.

Exclusion Criteria:

Received any investigational drug within 30 days of start of study or within 5½ half-lives (pharmacokinetic or pharmacodynamics) prior to enrollment (whichever is longer).
Are ineligible to receive treatment with:

Any preoperative active significant infection
Antibiotic sensitivity to Doxycycline and/or tetracycline family of drugs
Known allergies to more than 3 substances.(Patients should fill the allergy questioners during the enrolment process)
History of allergic/hypersensitivity reaction to any substance having required hospitalization and/or treatment with intra-venous steroids/epinephrine or in the opinion of the investigator the patient is at high risk of developing severe allergic / hypersensitivity reactions.
History of uncontrolled Asthma (GINA III-IV)
History of chronic urticaria

Pregnant or breastfeeding women.
Subjects who have taken oral or IV doxycycline during the last 4 weeks prior to screening.
Subjects who undergo cardiac/open chest surgeries, which are classified as emergency.
Immunocompromised subjects from any reason, at screening.
Subjects that undergone TIA/ CVA within the last 3 months prior to enrollment.
Subjects that previously underwent any cardiac surgery through mid-sternum.
In the opinion of investigator, subject is not eligible to participate in the study due to a cognitive status, medical condition or medication status (other than items listed above)

Contacts and Locations

Locations

	Site	City	Country
1	Soroka Medical Center	Beer sheva	Israel
2	Rambam Medical Center	Haifa	Israel
3	Assuta Medical Center	Tel Aviv	Israel
4	Sheba Medical Center	Tel Hashomer	Israel
5	Poriya Medical Center	Tiberias	Israel